- Home
- ANEB vs CALC Comparison
ANEB vs CALC Comparison
Compare ANEB & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- CALC
- Stock Information
- Founded
- ANEB 2020
- CALC 2011
- Country
- ANEB United States
- CALC United States
- Employees
- ANEB N/A
- CALC N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- CALC Health Care
- Exchange
- ANEB Nasdaq
- CALC Nasdaq
- Market Cap
- ANEB 111.8M
- CALC 45.4M
- IPO Year
- ANEB 2021
- CALC N/A
- Fundamental
- Price
- ANEB $2.56
- CALC $3.22
- Analyst Decision
- ANEB Buy
- CALC Strong Buy
- Analyst Count
- ANEB 2
- CALC 2
- Target Price
- ANEB $8.00
- CALC $14.50
- AVG Volume (30 Days)
- ANEB 29.2K
- CALC 54.6K
- Earning Date
- ANEB 11-12-2025
- CALC 11-12-2025
- Dividend Yield
- ANEB N/A
- CALC N/A
- EPS Growth
- ANEB N/A
- CALC N/A
- EPS
- ANEB N/A
- CALC N/A
- Revenue
- ANEB N/A
- CALC N/A
- Revenue This Year
- ANEB N/A
- CALC N/A
- Revenue Next Year
- ANEB N/A
- CALC N/A
- P/E Ratio
- ANEB N/A
- CALC N/A
- Revenue Growth
- ANEB N/A
- CALC N/A
- 52 Week Low
- ANEB $0.80
- CALC $1.42
- 52 Week High
- ANEB $3.42
- CALC $5.65
- Technical
- Relative Strength Index (RSI)
- ANEB 56.80
- CALC 52.18
- Support Level
- ANEB $2.30
- CALC $3.13
- Resistance Level
- ANEB $2.74
- CALC $3.33
- Average True Range (ATR)
- ANEB 0.14
- CALC 0.20
- MACD
- ANEB 0.03
- CALC -0.01
- Stochastic Oscillator
- ANEB 65.00
- CALC 36.76
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.